Keya Medical
AI for Smarter Healthcare
About
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating products that empower healthcare providers by optimizing efficiency, improving accuracy, and increasing precision.
Keya Medical has developed solutions for specialties including cardiology, radiology, neurology, pathology, and surgery. Since 2016, we have collaborated with more than 725 hospitals to improve care delivery on a global scale.
Diagnostic Solutions
Treatment Solutions
Core Products
DeepVessel FFR
DeepVessel FFR* uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
*CE Marked, National Medical Products Administration (NMPA) Approved. Not for sale in the United States.
CuraRad® – ICH
R&D Pipeline
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment maintenance.
Latest News
Dr. Kunlin Cao Named to 2021 Forbes China Up-and-Coming Businesswomen List
Keya Medical’s President of R&D, Dr. Kunlin Cao, has been recognized on the 2021 Forbes China Up-and-Coming Businesswomen list. The list highlights 20 accomplished women who have each played a significant role in shaping China’s business landscape.
The Value of Deep Learning-based CT-FFR in Detecting Coronary Stenosis & Predicting Outcomes
Researchers at Fuwai Hospital conducted a retrospective study to evaluate the performance of Keya Medical’s deep learning-based CT-FFR product in detecting hemodynamic changes in stenosis.
Putting the Spotlight on Women’s Hearts: Cardiovascular Disease in Women
Cardiovascular disease (CVD) remains the leading cause of death for women in the U.S. In honor of American Heart Month, we are highlighting the differences in women’s risk factors and primary prevention to help manage CVD in women.
Let’s transform the future of healthcare together
